34 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
6
Affinity-Based Selectivity Profiling of an In-Class Selective Competitive Inhibitor of Acyl Protein Thioesterase 2.
University of Michigan
15
Non-symmetrical furan-amidines as novel leads for the treatment of cancer and malaria.
University of Manchester
35
Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2.
Purdue University
39
A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site.
Lanzhou University
3
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
Caprotec Bioanalytics
5
Synthesis of novel¿¿3 receptor ligands via an unusual Knoevenagel condensation.
Moscow State University
34
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
H. Lundbeck
26
Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
Purdue University
17
Design, synthesis, and biological evaluation of potent quinoline and pyrroloquinoline ammosamide analogues as inhibitors of quinone reductase 2.
Purdue University
19
Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.
University of Manchester
25
Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from Streptomyces species, strain CNS284.
Purdue University
11
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
University of Lille
40
In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
University of Manchester and Manchester Cancer Research Center
18
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.
The University of Manchester and Manchester Cancer Research Center
16
Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.
University of Manchester and Manchester Cancer Research Center
48
Advancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103.
H. Lundbeck
29
Discovery of potent quinone oxidoreductase 2 inhibitors to overcome TRAIL resistance of non-small cell lung cancer.
Shandong University
2
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
University of Cambridge
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
20
Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors.
Purdue University
35
Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.
Takeda Chemical Industries
12
Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3).
Institut De Chimie Pharmaceutique Albert Lespagnol
9
Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties.
Instituto de Quimica Midica (IQM-CSIC)
30
Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
University of Manchester
7
Evaluation of analogues of furan-amidines as inhibitors of NQO2.
University of Manchester
11
Oxindole-based intraocular pressure reducing agents.
Lomonosov Moscow State University
14
Oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
Hoffmann-La Roche